Pioneering Life Science Investment for Long-Term Growth and Patient Impact
Syncona is a leading life science investor with a strong balance sheet and clear strategy for growth and patient impact. The core premise of our investment strategy is that significant risk-adjusted returns in life science come when novel technology is developed to a late-stage clinical product. We apply a differentiated investment model and take a long-term approach to build world-class companies which can reach this point.
We invest to extend and enhance human life
We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders.
OUR BUSINESS IN NUMBERS
Unless stated all finance at 30 June 2024
13
Portfolio companies
£739m
Value of life science portfolio
£421m
Capital pool
37
Members of the team
92%
Investment team with PhDs
23
Portfolio company Board seats
A vision to unlock the potential from truly innovative science to transform patients’ lives
From the start, Syncona has focused on building and scaling companies that transform groundbreaking science into therapies for patients with unmet medical needs. Our mission remains to deliver impactful healthcare solutions by turning exceptional scientific discoveries into real-world treatments.
We invest to extend and enhance human life. We have a strong, entrepreneurial culture, where everyone takes personal ownership for delivering Syncona’s mission. Our culture is underpinned by our values
The life sciences investment team members have deep technical scientific backgrounds, supplemented by strong commercial experience ranging from venture capital investment to pharmaceutical launch.
